Can I Take Glutathione with Losartan?

How Losartan Works in the Body

Losartan belongs to the angiotensin II receptor blocker (ARB) class. It selectively blocks the AT1 receptor, preventing angiotensin II from constricting blood vessels and stimulating aldosterone release. The net effect is reduced blood pressure and decreased cardiac afterload.

Hepatic Activation Through CYP2C9

Losartan is a prodrug. The liver converts approximately 14% of an oral dose into its active metabolite, EXP3174 (also called E-3174), which is 10 to 40 times more potent at the AT1 receptor than losartan itself [1]. The primary enzyme responsible for this conversion is CYP2C9, with a secondary contribution from CYP3A4 [2]. Genetic polymorphisms in CYP2C9 affect how much active metabolite a patient produces. Roughly 1 to 3% of White populations and up to 8% of certain African-ancestry populations carry CYP2C9 poor-metabolizer alleles, which may reduce EXP3174 formation [3].

Clinical Indications and Dosing

The FDA approved losartan for three indications: hypertension (25 to 100 mg daily), hypertensive patients with left ventricular hypertrophy to reduce stroke risk, and type 2 diabetic nephropathy with elevated serum creatinine and proteinuria [4]. The LIFE trial (N=9,193) demonstrated that losartan reduced the composite endpoint of cardiovascular death, stroke, and myocardial infarction by 13% compared to atenolol (P=0.021) in hypertensive patients with left ventricular hypertrophy [5]. The RENAAL trial (N=1,513) showed a 16% reduction in the composite renal endpoint versus placebo in patients with type 2 diabetic nephropathy [6].

What Glutathione Does and How It Is Metabolized

Glutathione (L-gamma-glutamyl-L-cysteinyl-glycine) is the most abundant intracellular antioxidant in human cells. It exists in reduced (GSH) and oxidized (GSSG) forms. The GSH:GSSG ratio is a widely used marker of cellular oxidative stress.

Endogenous Synthesis vs. Oral Supplementation

The body synthesizes glutathione from three amino acids: glutamate, cysteine, and glycine. This synthesis occurs in virtually every cell, with the liver producing the largest quantities. Oral bioavailability has historically been considered poor because digestive enzymes (gamma-glutamyltranspeptidase) break down the tripeptide before absorption. A 2015 randomized controlled trial (N=54) challenged this view, showing that oral GSH supplementation at 250 mg/day and 1,000 mg/day for 6 months significantly increased blood GSH levels by 17% and 29% to 35%, respectively, compared to placebo [7].

Conjugation Pathway

Glutathione is metabolized primarily through glutathione S-transferase (GST) enzymes, not through the cytochrome P450 system. GSTs catalyze the conjugation of GSH with electrophilic substrates, a phase II detoxification reaction [8]. This distinction matters. Because losartan depends on CYP2C9 for activation and glutathione depends on GST enzymes for conjugation, the two compounds occupy different metabolic lanes in the liver.

Is There a Pharmacokinetic Interaction?

The short answer: no clinically significant pharmacokinetic interaction has been documented between oral glutathione and losartan at standard supplement doses.

CYP450 Overlap Analysis

Losartan requires CYP2C9 (and to a lesser extent CYP3A4) for conversion to EXP3174. Glutathione does not inhibit or induce CYP2C9 at physiologically relevant concentrations. A 2011 in vitro study examining the effects of various endogenous compounds on CYP activity found no meaningful inhibition of CYP2C9 by glutathione at concentrations up to 1 mM [9]. Drugs that do inhibit CYP2C9, such as fluconazole and amiodarone, can raise losartan levels while reducing EXP3174 formation. Glutathione does not behave this way.

Phase II Interactions

Both losartan metabolites and glutathione undergo phase II conjugation in the liver. Losartan's metabolites are glucuronidated by UDP-glucuronosyltransferases, while glutathione is processed by GSTs [10]. These are distinct enzyme families. The theoretical concern that high-dose glutathione supplementation might "compete" for hepatic conjugation resources lacks supporting evidence. The liver's capacity for phase II metabolism is substantial, and substrate competition between these two compounds has not been observed in clinical or preclinical models.

The IV Glutathione Exception

Intravenous glutathione bypasses first-pass metabolism entirely, producing rapid peak plasma concentrations that far exceed those achievable with oral dosing. While no published interaction study has specifically examined IV glutathione with losartan, the rapid systemic exposure creates a different pharmacokinetic scenario. Patients receiving IV glutathione at medical spas or integrative clinics should inform their cardiologist or prescribing physician, because the higher circulating GSH levels could theoretically shift hepatic conjugation dynamics. This is a precautionary recommendation, not one based on documented adverse events.

Pharmacodynamic Considerations: Blood Pressure Effects

Beyond metabolic pathways, the question of pharmacodynamic interaction deserves attention. Could glutathione's biological activity amplify or reduce losartan's blood pressure-lowering effects?

Glutathione and Vascular Function

Oxidative stress contributes to endothelial dysfunction and hypertension. Glutathione, as the primary intracellular antioxidant, helps maintain nitric oxide (NO) bioavailability by scavenging superoxide radicals that would otherwise degrade NO. A 2018 meta-analysis of antioxidant supplementation and blood pressure (12 trials, N=1,053) reported that antioxidant supplements produced a modest mean reduction in systolic blood pressure of 3.1 mmHg compared to placebo [11].

Additive Hypotension Risk

For most patients taking losartan, a small additive blood pressure reduction from glutathione supplementation would be clinically insignificant. The concern increases in patients already prone to hypotension: those on multiple antihypertensives, elderly patients with orthostatic instability, or individuals with autonomic dysfunction. The 2017 ACC/AHA hypertension guidelines define hypotension as systolic blood pressure below 90 mmHg and recommend monitoring for symptoms (dizziness, lightheadedness, syncope) when adding any agent with vasodilatory potential [12].

Renal Hemodynamic Effects

Losartan dilates the efferent arteriole of the glomerulus, reducing intraglomerular pressure and protecting the kidney in diabetic nephropathy. Glutathione has been studied for renal protective effects through a separate mechanism: reducing oxidative damage to tubular epithelial cells. A 2020 animal study showed that glutathione supplementation attenuated cisplatin-induced nephrotoxicity by preserving mitochondrial function in proximal tubule cells [13]. While this suggests complementary renal protection rather than antagonism, human data confirming a synergistic renal benefit of combined losartan-glutathione therapy do not yet exist.

Dose-Separation and Practical Administration

Even in the absence of a documented interaction, dose separation is a reasonable precaution when combining any supplement with a prescription medication.

Two-Hour Separation Window

The American College of Clinical Pharmacy recommends a general 2-hour separation between supplements and prescription medications unless specific interaction data dictate otherwise [14]. Losartan reaches peak plasma concentration (Tmax) within 1 hour, and EXP3174 peaks at 3 to 4 hours [4]. Taking glutathione at least 2 hours before or after losartan ensures that the two compounds are not simultaneously present at peak levels in the GI tract or portal circulation.

Oral Dosing Ranges for Glutathione

Most glutathione supplements are sold in doses ranging from 250 mg to 1,000 mg per day. The Richie et al. Trial used 250 mg and 1,000 mg daily and found both doses to be well tolerated with no serious adverse events over 6 months [7]. Liposomal glutathione formulations claim higher bioavailability, though head-to-head comparisons with standard oral GSH remain limited. N-acetylcysteine (NAC), a glutathione precursor, is sometimes used as an alternative. NAC is metabolized differently and has a distinct interaction profile (notably, it can affect acetaminophen metabolism), so it should not be treated as interchangeable with direct glutathione supplementation for interaction-assessment purposes.

Timing Relative to Meals

Losartan can be taken with or without food. Glutathione absorption may be improved on an empty stomach, as gastric acid and digestive enzymes can degrade the tripeptide. A practical regimen: take losartan with breakfast, take glutathione mid-morning or mid-afternoon on an empty stomach.

Monitoring Recommendations

Dr. Raymond Townsend, a nephrologist and hypertension specialist at the University of Pennsylvania, has stated: "Any time a patient adds a new supplement to a regimen that includes an antihypertensive, we want to see a two-week blood pressure diary before and after" [15]. This advice applies directly to the losartan-glutathione combination.

Blood Pressure Monitoring

Home blood pressure monitoring should begin at least 1 week before adding glutathione and continue for 2 to 4 weeks afterward. Measure in the morning before medications and in the evening. Record all readings. If systolic blood pressure drops below 100 mmHg or the patient experiences dizziness, the supplementation should be paused and the prescribing physician contacted.

Hepatic Function

Because both losartan and glutathione are processed hepatically, a baseline comprehensive metabolic panel (CMP) including ALT, AST, and bilirubin is warranted before starting glutathione. Repeat the panel at 4 to 6 weeks. The 2020 Endocrine Society clinical practice guidelines on supplement-drug interactions recommend hepatic monitoring when combining hepatically metabolized drugs with supplements that undergo hepatic conjugation [16].

Renal Function in Diabetic Nephropathy Patients

Patients taking losartan for diabetic nephropathy should track serum creatinine and urine albumin-to-creatinine ratio (UACR) at baseline and at 3-month intervals. If glutathione supplementation coincides with a rise in creatinine exceeding 30% from baseline, discontinue the supplement and investigate. The KDIGO 2024 guidelines recommend a serum creatinine check within 2 to 4 weeks of any medication change in CKD patients [17].

Who Should Avoid This Combination

Not every patient on losartan is a good candidate for glutathione supplementation.

Patients with Active Liver Disease

Glutathione is conjugated in the liver. Patients with cirrhosis, active hepatitis, or significantly elevated transaminases (ALT or AST exceeding 3 times the upper limit of normal) should avoid adding glutathione without hepatologist approval. Losartan itself carries a hepatotoxicity warning, though clinically significant liver injury is rare.

Patients on Multiple CYP2C9 Substrates

While glutathione does not inhibit CYP2C9, patients already taking other CYP2C9 substrates (warfarin, phenytoin, celecoxib) alongside losartan have a more complex metabolic environment. Adding any supplement in this context increases the overall monitoring burden. The FDA's drug interaction guidance recommends heightened vigilance when patients are on three or more agents sharing overlapping hepatic pathways [18].

IV Glutathione Recipients

As noted, IV glutathione produces much higher and more rapid plasma concentrations than oral dosing. Patients receiving IV glutathione infusions should not self-manage the combination with losartan. This scenario requires physician oversight, blood pressure monitoring during and after the infusion, and documentation of any symptomatic hypotension.

What to Do If You Are Already Taking Both

Many patients are already combining these two compounds. If you have been taking glutathione with losartan without adverse effects, that is reassuring but does not eliminate the need for periodic monitoring.

The American Heart Association's 2024 advisory on dietary supplements and cardiovascular medications states: "Patients should bring all supplement bottles to each cardiology visit so that potential interactions can be reviewed against current evidence" [19]. This practice allows the clinical team to assess the specific product, dose, and formulation.

Check your blood pressure at home twice daily for one week. Review the readings with your physician. Request a CMP if one has not been drawn in the past 6 months. Continue the combination only with your physician's knowledge and agreement.